✓ verbatim from the press ? no verbatim passage
The Brazilian Health Surveillance Agency (Anvisa) authorized on Friday (29) the resumption of production at the Ypê factory in Amparo (SP), after concluding that Química Amparo corrected the main sanitary violations identified in previous inspections. The decision allows the company to resume operations immediately and market products manufactured from April 1, 2026. ✓
Press quotes (1)
"A Agência Nacional de Vigilância Sanitária (Anvisa) autorizou nesta sexta-feira (29) a retomada da produção na fábrica da Ypê, em Amparo, no interior de São Paulo, após concluir que a empresa corrigiu parte das falhas sanitárias identificadas em inspeções anteriores."
The authorization came after a joint reinspection conducted by Anvisa, the São Paulo Health Surveillance Center, the Campinas Health Surveillance Group, and Amparo Health Surveillance. According to the agency, the company presented a plan to meet 76 sanitary requirements identified during an inspection conducted in April. "We verified that this Ypê factory now meets the necessary conditions to operate safely and provide products without sanitary risk to the Brazilian population," said Anvisa president Leandro Safatle. ✓
Press quotes (1)
"Verificamos que esta fábrica da Ypê já reúne as condições necessárias para operar com segurança e disponibilizar produtos sem risco sanitário para a população brasileira", afirmou em nota o presidente da agência, Leandro Safatle."
Despite the factory resumption, products with batch numbers ending in "1" manufactured until March 31, 2026, remain prohibited for sale and use. According to Anvisa, these products must remain stored in a safe location and their release depends on presenting reports from laboratories authorized by the agency. Pseudomonas aeruginosa can cause infections in people with low immunity, such as cancer patients, transplant recipients, and elderly individuals. ?
Press quotes (2)
"A Agência Nacional de Vigilância Sanitária (Anvisa) determinou, nesta quinta-feira (7/5), o recolhimento de produtos lava-louças (detergente), sabão líquido para roupas e desinfetante da marca Ypê, de todos os lotes com numeração final 1. Os itens foram fabricados pela empresa Química Amparo (CNPJ 43.461.789/0001-90), na unidade localizada em Amparo (SP)."
"Unilever filed the first report against Ypê with Anvisa in October 2025, six months before the public suspension of the products. According to the documents, the multinational identified the presence of the bacteria Pseudomonas aeruginosa/paraaeruginosa in four batches of Tixan Ypê Express."
Anvisa authorized resumption of Ypê factory production on May 29, 2026
Company presented plan to meet 76 sanitary requirements
Covered by only some sources, or where the accounts diverge.
Covered by only some sources (2)
Anvisa issued three different communications about authorization on the same day
Conflicting versions (1)
Cut-off date for released products
-
What specifically constitutes the 'final batch 1' mentioned in Anvisa's decisions?
Why it's still unknown: The technical terminology was not clarified by the agency or company in public communications
-
What were the specific technical reports from Charles River and Eurofins laboratories mentioned in Unilever's complaints?
Why it's still unknown: Attempt to obtain formal documents of Unilever's complaints filed with Anvisa failed - files not located in Official Gazette or Anvisa portal
-
Why did Anvisa issue contradictory communications about product authorization on May 29?
Why it's still unknown: Sources mention three different versions of communications (17h21, 18h18, 22h42) but do not explain reasons for corrections